As early as can be traced, written documents testify endeavors shown by humanity to please by means of the hair. Hair care, color and style play an important role in people’s physical appearance and self-perception. Dermatologists should be knowledgeable about the procedures people follow to look their best and should have the competence to provide patients with information on the benefits and hazards of hair cosmetics and pharmaceuticals. Shampooing is the most common form of cosmetic hair treatment. The diversity of qualities expected from a shampoo by today’s consumer surpass the primary function of cleansing. Current shampoo formulations are adapted to the variations associated with hair quality, hair care habit and specific problems related to the superficial condition of the scalp. Hand in hand, test methods are developed to evaluate the efficacy of hair care products so that consumers are offered products that perform as claimed. Through the development of cosmetics with pharmaceutically active compounds, products are evolving that are becoming more similar to topical therapeutic agents (cosmeceuticals). The efficacy of cosmeceuticals that claim to act as hair growth stimulants should be measured by the standards set by the drugs minoxidil and, more recently, oral finasteride. Finally, health hazards associated with the use of hair care products, especially rinse-off products, have been overemphasized by the media and need careful correction by opinion leaders.

Giacometti L: Facts, legends, and myths about the scalp throughout history. Arch Dermatol 1967;95:628–631.
Trüeb RM: Von der Hippokratischen Glatze zum Gen-Shampoo: Fortschritte der Trichologie im Jahrtausendwechsel. Akt Dermatol 1998;24:101–107.
Tischer B: Einfluss von Haarausfall auf Personalentscheidungen. Pullach, TNS EMNID Healthcare, 2000.
Zesch A: Kosmetika: Definition und rechtliche Grundlagen. Hautarzt 1999;50:243–249.
Egli RJ: The cosmetic-drug regulatory distinction; in Hori W (ed): Drug Discovery Approaches for Developing Cosmeceuticals: Advanced Skin Care and Cosmetic Products. Southborough, IBC Library Series, 1997, pp 1.2.1–1.2.26.
Hammes C: Cosmeceuticals: The cosmetic-drug borderline; in Hori W (ed): Drug Discovery Approaches for Developing Cosmeceuticals: Advanced Skin Care and Cosmetic Products. Southborough, IBC Library Series, 1997, pp 1.1.1–1.1.7.
Dooley TP: Is there room for a moderate level of regulatory oversight? in Hori W (ed): Drug Discovery Approaches for Developing Cosmeceuticals: Advanced Skin Care and Cosmetic Products. Southborough, IBC Library Series, 1997, pp 1.4.1–1.4.16.
Bouillon C: Shampoos. Clin Dermatol 1996;14:113–121.
Trüeb RM: Haarwaschmittel (Shampoos): Zusammensetzung und klinische Anwendungen. Hautarzt 1998;49:895–901.
Price SNC: 50 years of surfactants: Cosmetic cleansing and emulsions. Cosmetics Toiletries 1995;110:49–66.
Rushton H, Gummer CL, Flasch H: 2-in-1 shampoo technology: State-of-the-art shampoo and conditioner in one. Skin Pharmacol 1994;7:78–83.
Ishii MK: Objective and instrumental methods for evaluation of hair care product efficacy and substantiation of claims; in Johnson DH (ed): Hair and Hair Care. Cosmetic Science and Technology Series. New York, Dekker, 1997, pp 261–302.
Shapiro J, Maddin S: Medicated shampoos. Clin Dermatol 1996;14:123–128.
Dawber RPR: Shampoos – Scientific basis and clinical aspects. International Congress and Symposium Series 216. London, Royal Society of Medicine Press, 1997.
Mahé YF, Buan B, Bernard BA: A minoxidil-related compound lacking a C6 substitution still exhibits strong anti-lysyl hydroxylase activity in vitro. Skin Pharmacol 1996;9:177–183.
Jaworsky C, Kligman AM, Murphy GF: Characterization of inflammatory infiltrates in male pattern alopecia: Implications for pathogenesis. Br J Dermatol 1992;127:239–246.
Courtois M, Loussouarn G, Hourseau C, Grollier JF: Periodicity in the growth and shedding of hair. Br J Dermatol 1996;134:47–54.
Kaufman KD, Olsen EA, Whiting D, Savin R, De Villez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ: Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39:578–589.
Van Neste D, Fuh V, Sanchez-Pedreno P, Lopez-Bran E, Wolff H, Whiting D, Roberts J, Kopera D, Stene JJ, Calvieri S, Tosti A, Prens E, Guarrera M, Kanojia P, He W, Kaufman KD: Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol 2000;143:804–810.
Philpott MP, Sanders DA, Bowen J, Kealey T: Effects of interleukins, colony-stimulating factor and tumour necrosis factor on human hair follicle growth in vitro: A possible role for interleukin-1 and tumour necrosis factor-alpha in alopecia areata. Br J Dermatol 1996;135:942–948.
Li L, Hoffman RM: The feasibility of targeted selective gene therapy on the hair follicle. Nat Med 1995;1:705–706.
Stenn KS: Critical pathways of hair follicle growth control: Approaches for a drug discovery program; in Hori W (ed): Drug Discovery Approaches for Developing Cosmeceuticals: Advanced Skin Care and Cosmetic Products. Southborough, IBC Library Series, 1997, pp 4.1.1–4.1.14.
Philpott MP, Green MR, Kealey T: Human hair growth in vitro. J Cell Sci 1990;97:463–471.
Uno H: Stumptailed macaques as a model of male-pattern baldness; in Maibach HI, Lowe NJ (eds): Models in Dermatology. Basel, Karger, Basel 1987, pp 159–169.
Van Neste D, de Brouwer B, Dumortier M: Reduced linear growth rates of vellus and of terminal hairs produced by human balding scalp grafted onto nude mice: The molecular and structural biology of hair. Ann NY Acad Sci 1991;642:480–482.
Jahoda CAB, Reynolds AJ: Dermal-epidermal interactions – Follicle-derived cell populations in the study of hair-growth mechanisms. J Invest Dermatol 1993;101:33S–38S.
Ahmad W, Faiyaz ul Haque M, Brancolini V, Tson HC, ul Haque S, Lam H, Aita VM, Owen J, de Blaquiere M, Frank J, Cserhalmi-Friedman PB, Leask A, McGrath JA, Peacocke M, Ahmad M, Ott J, Christiano AM: Alopecia universalis associated with a mutation in the human hairless gene. Science 1998;279:720–724.
Consumers’ Association: Reactions of the Skin to Cosmetics and Toiletry Products. London, Consumers’ Association, 1979.
De Groot AC: Labeling cosmetics with their ingredients. Br Med J 1990;300:1636–1638.
De Groot AC, Beverdam E, Ayong CT, Coenraads PJ, Nater JP: The role of contact allergy in the spectrum of adverse effects caused by cosmetics and toiletries. Contact Dermatitis 1988;19:195–201.
Menné T, Hjorth N: Routine testing with paraben esters. Contact Dermatitis 1988;19:189–191.
De Groot AC, White IR: Cosmetics and skin care products; in Rycroft RJC, Menné T, Frosch PG, Benezra C (eds): Textbook of Contact Dermatitis. Berlin, Springer, 1992, pp 459–475.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.